influenza
contagi
acut
respiratori
diseas
caus
influenza
viru
infect
caus
mild
sever
ill
time
lead
peopl
contract
influenza
recov
sever
day
less
two
week
peopl
develop
complic
annual
epidem
result
high
number
hospit
estim
million
sever
case
death
global
young
children
adult
age
year
older
pregnant
women
peopl
certain
chronic
diseas
among
high
risk
seriou
flu
complic
possibl
requir
hospit
sometim
result
influenza
infect
account
major
hospit
type
caus
global
pandem
outbreak
http
wwwwhoint
influenza
virus
divid
subtyp
base
two
protein
viral
surfac
hemagglutinin
ha
neuraminidas
na
differ
hemagglutinin
subtyp
differ
neuraminidas
subtyp
ha
molecul
initi
infect
bind
receptor
specif
host
cell
na
possess
receptor
destroy
activ
cleav
termin
sialic
acid
residu
cellsurfac
glycoprotein
gangliosid
releas
progeni
viru
host
cell
import
target
influenza
viru
therapeut
treatment
diagnost
detect
influenza
virus
constantli
chang
two
differ
way
antigen
drift
antigen
shift
antigen
drift
mechan
virus
accumul
mutat
within
gene
occur
continu
time
viru
replic
chang
ha
protein
allow
viru
escap
preexist
immun
antigen
shift
sudden
chang
antigen
influenza
viru
antigen
shift
result
direct
jump
unknown
anim
strain
human
reassort
two
influenza
virus
within
cell
result
new
viru
ha
hana
combin
emerg
anim
popul
differ
subtyp
human
peopl
immun
new
viru
new
virus
may
caus
antigen
drift
occur
type
influenza
virus
antigen
shift
howev
occur
flu
infect
human
vaccin
effect
way
prevent
influenza
infect
moder
efficaci
good
safeti
accept
toler
howev
vaccin
lack
crossprotect
exhibit
unsatisfactori
efficaci
highrisk
popul
includ
older
peopl
young
children
immunocompromis
patient
addit
vaccin
gener
treatment
prophylaxi
influenza
limit
neuraminidas
inhibitor
oseltamivir
tamiflu
zanamivir
relenza
confirm
case
influenza
infect
treat
zanamivir
oseltamivir
administ
within
h
onset
clinic
symptom
drug
reduc
durat
ill
day
patient
age
baloxavir
marboxil
xofluza
novel
select
inhibitor
influenza
capdepend
endonucleas
influenza
b
virus
approv
fda
treatment
acut
uncompl
influenza
peopl
year
age
older
symptomat
howev
influenza
viru
rapidli
acquir
resist
drug
mutat
viral
compon
season
isol
resist
oseltamivir
unit
state
japan
south
addit
two
influenza
virus
carri
substitut
polymeras
acid
subunit
pa
show
reduc
suscept
patient
infect
baloxavirresist
virus
exhibit
prolong
viru
shed
median
time
symptom
allevi
longer
baloxavir
recipi
infect
virus
bear
substitut
infect
virus
lack
emerg
drug
resist
short
treatment
window
antivir
drug
unsatisfactori
efficaci
current
avail
vaccin
unmet
medic
need
influenza
therapi
influenza
virusneutr
antibodi
elicit
via
vaccin
infect
bind
globular
head
ha
block
interact
viral
sialic
acid
receptor
host
cell
recent
sever
studi
shown
influenzaneutr
antibodi
target
conserv
epitop
influenza
viru
might
offer
altern
treatment
passiv
immunotherapi
use
antiinfluenza
antibodi
potenti
prevent
treat
influenza
ideal
neutral
antibodi
exhibit
potent
effect
direct
viral
neutral
induc
antibodydepend
cellular
cytotox
antibodydepend
cellular
phagocytosi
complementdepend
cytotox
vitro
vivo
studi
identifi
human
influenza
viru
neutral
antibodi
via
epsteinbarr
viru
ebv
immort
b
cellbas
technolog
interact
specif
ha
head
portion
character
mode
bind
analyz
complex
crystal
structur
fragment
antigenbind
fab
antigen
describ
experiment
section
see
summar
fig
human
monoclon
antibodi
neutral
influenza
viru
obtain
peripher
blood
vaccin
healthi
volunt
use
ebvbas
strategi
peripher
memori
b
cell
isol
healthi
donor
immort
via
ebv
clone
bind
neutral
activ
screen
select
enzymelink
immunosorb
assay
elisa
neutral
assay
base
potenc
antibodi
clone
chosen
lead
clone
character
use
number
techniqu
includ
elisa
cellbas
neutral
assay
well
surfac
plasmon
reson
spr
verifi
specif
monoclon
antibodi
viru
addit
elisa
perform
use
also
two
strain
name
shown
fig
specif
bind
profil
follow
hyperbol
curv
suggest
strong
interact
antibodi
viru
contrast
weak
bind
observ
either
bind
partner
specif
also
examin
via
neutral
assay
shown
fig
show
strong
neutral
abil
viru
profil
neutral
activ
also
turn
hyperbol
half
maxim
effect
concentr
calcul
fig
show
littl
activ
strain
fig
summari
specif
monoclon
antibodi
intact
antibodi
contain
two
antigenbind
site
two
fab
fulllength
ha
divid
two
region
hemagglutinin
head
domain
hemagglutinin
stalk
domain
may
form
trimer
via
judg
natur
dival
antibodi
trimer
ha
ha
variat
differ
strain
occur
mainli
domain
bind
host
receptor
investig
kinet
profil
bind
ha
histag
fab
domain
residu
express
human
cell
purifi
subsequ
use
biacor
system
affin
molecul
determin
measur
bind
kinet
spr
singlecycl
kinet
use
interact
analysi
bind
protein
high
affin
fig
dissoci
constant
kd
valu
measur
onrat
kon
offrat
koff
influenza
virus
usual
underw
recombin
mutat
pandem
occurr
produc
new
strain
vari
antigen
determin
origin
antigen
sever
differ
clinic
isol
strain
pandem
subsequ
test
neutral
activ
shown
fig
six
clinic
isol
pandem
fail
recogn
wherea
five
isol
pandem
could
neutral
correspond
list
tabl
strain
slightli
higher
four
strain
rang
presum
isol
strain
close
relat
one
well
nevertheless
distinct
differ
six
isol
pandem
clear
understand
mechan
antibodi
capabl
neutral
larg
number
virus
cocrystal
complex
structur
determin
resolut
tabl
crystal
belong
space
group
four
complex
pack
asymmetr
unit
fig
complex
structur
one
fab
bound
top
globular
domain
fig
model
compris
heavi
chain
residu
light
chain
residu
togeth
bind
domain
residu
display
typic
immunoglobulin
fold
complementaritydetermin
region
cdr
well
lightchain
cdr
loop
compos
residu
cdr
heavi
chain
compos
residu
fig
influenza
hemagglutinin
contain
residu
transmembran
segment
residu
six
nlink
glycosyl
site
residu
predict
tmhmm
http
wwwcbsdtudkservicestmhmm
netglyc
program
http
wwwcbsdtudkservicesnetnglyc
domain
contain
three
predict
glycosyl
site
residu
complex
structur
glycosyl
monosaccharid
observ
sdngt
sequon
stabil
protein
structur
domain
along
glycan
contact
side
chain
fig
glycosyl
residu
remain
uncertain
wherea
glycosyl
residu
includ
complex
crystal
notabl
calcium
ion
bound
fig
site
glycosyl
calcium
bind
separ
one
anoth
later
surfac
molecul
neither
like
involv
interact
fab
base
domain
superimposit
complex
onto
ha
trimer
model
indic
block
bind
domain
trimer
via
mode
observ
crystal
structur
fig
steric
hindranc
observ
fab
two
domain
interatom
distanc
fab
region
domain
greater
appear
addit
interact
signific
howev
steric
hindranc
consider
ha
trimer
bound
anoth
fab
second
fab
would
clash
sever
first
one
consequ
via
observ
mode
bind
ha
trimer
like
bind
one
fab
molecul
use
one
domain
site
display
conform
epitop
locat
top
surfac
ha
major
region
compos
two
discontinu
linear
peptid
residu
residu
form
abreast
loop
conform
residu
two
loop
form
conform
epitop
recognit
paratop
consist
three
heavychain
cdr
two
lightchain
cdr
show
interact
antigen
heavi
chain
light
chain
surfac
area
buri
upon
complex
format
figur
show
interfac
interact
influenza
viru
ha
sidechain
hydroxyl
group
three
tyrosin
residu
sidechain
oxygen
atom
heavychain
cdr
provid
strong
hydrogen
bond
interact
residu
ha
molecul
three
water
molecul
observ
interfac
ha
heavi
chain
consist
observ
four
complex
show
lower
b
valu
averag
two
water
molecul
hydrogenbond
side
chain
heavi
chain
form
hydrogen
bond
ha
anoth
water
molecul
use
mediat
interact
heavychain
ha
watermedi
bond
provid
import
stabil
forc
intermolecular
interact
two
protein
residu
heavychain
cdr
exhibit
nonpolar
interact
residu
ha
fig
lightchain
cdr
residu
hydrogen
bond
residu
ha
residu
hydrophob
contact
ha
fig
major
surfac
protein
influenza
viru
ha
involv
receptor
bind
facilit
viral
entri
host
cell
conserv
receptorbind
site
rb
recogn
sialic
acid
host
surfac
glycan
locat
globular
head
domain
subsequ
conform
chang
stem
part
ha
lead
membran
fusion
viru
host
cell
releas
viral
influenza
viru
infect
vaccin
induc
robust
antibodi
two
type
antibodi
identifi
neutral
nonneutr
antibodi
convent
neutral
antibodi
bind
globular
head
ha
often
strainspecif
certain
neutral
antibodi
bind
conserv
stem
region
ha
provid
broadli
neutral
activ
mani
differ
strain
flu
gener
antiha
stem
antibodi
less
effect
viral
neutral
partli
stem
ha
solventexpos
bind
head
howev
mediat
nonneutr
function
antibodydepend
cellularmedi
cytotox
adcc
elimin
infect
number
broadli
protect
monoclon
antibodi
influenza
virus
isol
character
provid
inform
vaccin
design
use
antibodi
obtain
character
specif
strain
high
specif
reflect
result
elisa
cellbas
assay
affin
ha
measur
use
biacor
also
strong
consist
ident
bind
mode
four
independ
complex
observ
crystal
interestingli
unlik
antibodi
bind
ha
without
involv
rb
fig
interfac
adjac
triad
axi
ha
trimer
bind
addit
copi
fig
therefor
stoichiometri
ha
bind
contrast
ratio
known
fabha
complex
fig
haheadspecif
antibodi
bind
monomer
state
although
rb
block
directli
bulki
immunoglobulin
attach
top
surfac
ha
trimer
longer
bind
cellsurfac
receptor
furthermor
high
antibodi
concentr
high
ha
ratio
ha
may
tend
bind
one
fab
case
ha
trimer
would
disrupt
thu
unabl
interact
properli
host
receptor
mani
haneutr
antibodi
target
rb
mimick
host
sialoglycan
use
differ
strategi
interact
ha
buri
surfac
area
complex
format
fab
larger
known
complex
eg
pdb
howev
contemporan
presenc
sever
weak
bond
stabl
complex
form
interact
includ
direct
hydrogen
bond
hydrophob
contact
also
sever
watermedi
hydrogen
bond
allabout
medium
water
molecul
inde
easili
form
strong
hydrogen
bond
anoth
featur
particular
note
presenc
three
phenol
group
tyrosin
residu
interfac
addit
hydrogen
bond
form
hydroxyl
group
aromat
side
chain
tyrosin
heavychain
cdr
also
hydrophob
interact
nonpolar
residu
ha
sequenc
align
epitop
region
shown
fig
secondari
structur
residu
number
base
strain
studi
sequenc
recent
strain
older
strain
two
pdb
model
also
loop
structur
superimpos
fig
model
color
green
pink
asolomon
gray
orang
notabl
loop
much
longer
three
antibodi
bind
two
identifi
antigen
site
sa
sb
fig
locat
near
spike
epitop
includ
residu
sa
site
residu
sb
site
howev
differ
amino
acid
found
region
clinic
isol
pandem
recent
strain
conserv
epitop
serv
templat
neutral
potenti
antigen
site
cb
includ
epitop
six
clinic
isol
viru
pandem
fail
recogn
substanti
amino
acid
chang
sa
sb
site
antibodi
isol
elderli
survivor
pandem
crossneutr
exhibit
strong
bind
sa
site
diverg
antigen
surfac
human
viru
directli
correl
antibodi
crossreact
complex
structur
clearli
elucid
epitopecdr
interact
interfac
also
involv
three
order
mediat
water
molecul
similar
anoth
high
affin
herp
simplex
viru
neutral
antibodi
investig
relationship
epitop
configur
affin
bind
region
compar
three
known
structur
pdb
rootmeansquar
deviat
rmsd
pair
correspond
atom
respect
last
complex
differ
speci
influenza
b
show
larg
structur
deviat
suppos
react
contrast
epitopecontain
loop
conform
virtual
ident
two
pdb
structur
structur
fig
nevertheless
sequenc
comparison
epitop
region
sa
sb
show
clear
distinct
along
associ
strain
fig
map
epitop
onto
surfac
equival
fig
reveal
similar
topolog
region
ident
locat
conserv
key
residu
interact
featur
share
postpandem
strain
found
prepandem
strain
includ
fig
high
mutat
rate
influenza
viru
annual
season
reformul
vaccin
necessari
confer
effect
protect
underli
reason
mutat
alter
surfac
epitop
recogn
antibodi
lose
abil
bind
strongli
virus
studi
isol
human
antibodi
specif
influenza
viru
show
effect
neutral
sever
differ
isol
pandem
also
known
swine
flu
combin
biochem
biophys
data
xray
crystallograph
analysi
good
structur
basi
laid
strain
specif
turn
mutat
epitop
surfac
affect
bind
find
mutat
escap
antibodi
bind
elucid
specif
epitopecdr
interact
use
detect
treatment
influenza
viru
infect
blymphoblastoid
cell
line
cell
cultur
rpmi
medium
contain
lglutamin
invitrogen
supplement
fetal
calf
serum
penicillinstreptomycin
humidifi
incub
madindarbi
canin
kidney
mdck
cell
cultur
dulbecco
modifi
eagl
medium
dmem
medium
invitrogen
supplement
fetal
calf
serum
spodoptera
frugiperda
cell
maintain
ii
sfm
invitrogen
ebv
immort
human
b
lymphocyt
prepar
cell
line
ebvproduc
marmoset
b
cell
line
use
sourc
ebv
transform
human
b
cell
cultur
supernat
collect
filter
steril
syring
filter
millipor
store
use
vaccin
strain
viru
viru
viru
obtain
medigen
vaccin
biolog
co
mvc
taiwan
influenza
viru
clinic
strain
provid
taiwan
cdc
use
recognit
assay
neutral
assay
propag
influenza
viru
clinic
strain
determin
tissu
cultur
infecti
dose
perform
mdck
cell
accord
reedmuench
method
experi
perform
accord
irb
guidelin
regul
b
cell
isol
prescreen
healthi
donor
follow
inform
consent
irb
approv
protocol
irb
number
taipei
veteran
gener
hospit
high
viru
titer
use
combin
ficol
densiti
gradient
centrifug
ge
healthcar
life
scienc
neg
b
cell
isol
kit
miltenyi
biotec
select
kit
miltenyi
biotec
follow
manufactur
memori
b
cell
infect
ebv
viru
accord
briefli
memori
b
cell
seed
plate
feeder
cell
gammairradi
allogen
mononuclear
cell
complet
medium
contain
cpg
invivogen
ngml
cyclosporin
sigmaaldrich
ebv
supernat
day
cultur
supernat
screen
antibodi
specif
ha
pandem
fulllength
cdna
desir
igg
clone
identifi
b
cell
clone
antibodi
express
elisa
perform
examin
habind
activ
sera
cultur
supernat
purifi
antibodi
briefli
inactiv
whole
viru
coat
plate
maxisorb
nunc
overnight
follow
block
bovin
serum
albumin
bsa
pb
invitrogen
h
serial
dilut
sampl
incub
well
h
complet
wash
horseradishperoxidaselabel
antihuman
igg
dilut
ad
incub
h
ad
develop
color
reaction
stop
amount
chromogen
produc
measur
base
absorb
nm
nm
use
elisa
reader
spectramax
md
us
neutral
assay
sera
antibodi
perform
describ
protocol
avail
world
health
organ
minor
briefli
sera
cell
cultur
supernat
purifi
human
monoclon
antibodi
serial
dilut
dmem
contain
bsa
incub
tissu
cultur
infecti
dose
clinic
isol
h
mixtur
ad
tpcktrypsin
pretreat
mdck
cell
cell
per
well
plate
incub
min
follow
mdck
cell
wash
pb
remov
supernat
contain
free
antibodi
viru
replac
fetal
bovin
serum
dmembas
complet
medium
anoth
h
cultur
mdck
cell
fix
paraformaldehyd
doubl
stain
antinucleoprotein
np
fluorescein
isothiocyan
fitc
label
antibodi
millipor
dapi
infect
effici
quantifi
analyz
use
highcont
imag
system
imagexpress
micro
molecular
devic
sunnyval
ca
usa
neutral
activ
antibodi
calcul
accord
equat
wherein
repres
cell
count
npdapidoubl
posit
cell
viru
infect
control
b
repres
cell
count
npdapidoubl
posit
cell
test
sampl
cdna
sequenc
correspond
domain
residu
ha
access
ctermin
histag
construct
pcdna
vector
invitrogen
protein
express
domain
express
cell
gibco
transient
transfect
use
expifectamin
transfect
kit
gibco
cultur
supernat
collect
purif
use
histrap
excel
prepack
column
ge
healthcar
histag
protein
elut
use
solut
contain
mm
sodium
phosphat
mm
nacl
mm
imidazol
ph
express
vector
deriv
igg
express
plasmid
pigg
us
patent
contain
domain
heavi
chain
contain
addit
histag
cterminu
domain
heavi
chain
also
express
cell
purifi
via
histrap
excel
column
use
gradient
mm
mm
imidazol
solut
mm
sodium
phosphat
mm
nacl
ph
fraction
contain
elut
mm
imidazol
singlecycl
kinet
measur
biacor
ge
healthcar
immobil
chip
ge
healthcar
reson
unit
ru
use
standard
procedur
amin
coupl
edcnh
reaction
five
differ
analyt
concentr
nm
use
cycl
constant
flow
rate
run
buffer
contain
mm
hepe
ph
mm
nacl
surfac
regener
cycl
associ
measur
sec
final
dissoci
time
sec
kinet
data
analyz
use
biacor
evalu
softwar
obtain
complex
purifi
premix
molar
ratio
overnight
mixtur
load
onto
gelfiltr
column
superdex
prepgrad
ge
healthcar
protein
complex
elut
flow
rate
mlmin
buffer
solut
consist
mm
tri
mm
nacl
ph
optic
absorb
nm
use
monitor
elut
protein
complex
complex
crystal
grown
mix
protein
solut
reservoir
solut
use
sittingdrop
vapordiffus
method
k
crystal
obtain
reservoir
solut
consist
wv
polyethylen
glycol
mm
calcium
acet
vv
glycerol
mm
sodium
cacodylatehydrochlor
acid
ph
crystal
flashcool
diffract
pattern
record
cryogen
temperatur
diffract
data
collect
wavelength
taiwan
photon
sourc
tp
beamlin
nation
synchrotron
radiat
research
center
nsrrc
taiwan
use
rayonix
ccd
detector
diffract
data
process
scale
use
complex
crystal
structur
determin
via
molecular
replac
use
softwar
pdb
entri
pdb
entri
fragment
search
model
complex
crystal
belong
space
group
four
complex
asymmetr
unit
throughout
refin
use
randomli
select
data
set
asid
crossvalid
rfree
valu
manual
modif
model
perform
use
program
complex
structur
refin
resolut
rwork
rfree
valu
respect
obtain
datacollect
final
model
statist
shown
tabl
molecular
figur
produc
use
atom
coordin
structur
factor
crystal
structur
complex
deposit
protein
data
bank
access
code
studi
approv
institut
review
board
irb
taipei
veteran
gener
hospit
irb
number
healthi
volunt
provid
written
inform
consent
particip
studi
